Dr. rer. nat. Saskia Rudat
Postdoctoral Research Fellow
Klinik / Institut / Zentrum
My overarching goal is to improve the treatment of leukemia patients through translational cancer research.
During my time as a PhD Student at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) in Heidelberg, and later as a Postdoctoral Fellow at the Wellcome Sanger Institute in Hinxton, Cambridgeshire, UK, my work has focused on identifying vulnerabilities in diverse types of leukemia, most notably acute myeloid leukemia (AML). Ultimately, my work has lead to the proposals of novel mechanism-based targeted therapies for specific subtypes of AML as described in Rudat et al. (Leukemia, 2018) and Supper, Rudat et al., (Nature Communications, 2021).
In my current position as a Postdoctoral Research Fellow at the University Hospital in Tübingen, my research involves clonal hematopoiesis of indeterminate potential (CHIP), as well as identifying immunomodulatory cell surface proteins and their regulation through CRISPR/Cas9 screens with the aim to improve cellular cancer immunotherapies in AML.
Ausbildung & beruflicher Werdegang
- since 09/2021Postdoctoral Research Fellow, University Hospital Tübingen, Tübingen, DE
- 01/2018-07/2021Postdoctoral Research Fellow, Wellcome Sanger Institute, Hinxton, UK
- 11/2012-12/2017PhD Student, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, DE
- 05/2012-10/2012Research Assistant, University Hospital Ulm, Ulm, DE
- 10/2006-04/2012Diploma Student of Molecular Biology, Ulm University, Ulm, DE
Preise & Auszeichnungen
- YoungEHA Best Abstract Award in the category for Postdoctoral Research Trainees - Jun 2019, 24th Congress of the European Hematology Association (EHA)
- Poster Prize Award - Dec 2016, 32nd Ernst Klenk Symposium in Molecular Medicine
- International Society for Experimental Hematology (ISEH) - since Mar 2022
- European Hematology Association - since Jan 2015